To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
CellGenix received ISO 9001:2008 certification
18-07-2012: CellGenix’ quality management system was certified in April 2012 on the requirements of DIN EN ISO 9001:2008 standard by the TÜV Rheinland Cert GmbH. To highlight CellGenix’ commitment to quality and service the certification of ISO 9001:2008 covers all relevant functions of the company, development, production, storage and distribution of CellGenix’ Ex Vivo Therapeutics, i.e. growth factors, serum-free media and cell culture systems.
“With more than 15 years of experience in GMP cell processing and over 10 years in GMP production of recombinant protein pharmaceuticals, production and quality control have always been under regulatory surveillance of authorities. The implementation of the requirements of ISO 9001:2008 has improved structuring of our daily tasks in all work areas and documents our total quality approach,” said Dr. Stefan Thoma, CellGenix’ Director Quality Management.
Contact / Request information
Request further information free of charge:
This is where you can add this news to your personal favourites
- 1Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
- 2Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 3Vivacta Initiates Development of Point of Care Test for Vitamin D
- 4Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
- 5Researchers divide enzyme to conquer genetic puzzle
- 6A light switch inside the brain
- 7Merck & Co., Inc. Opens Asia Pacific Regional Headquarters in Singapore
- 8Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.
- 9New study confirms fungal infection of the foot is a risk factor for bacterial tissue infection of the leg
- 10MIV-210 - a potential drug against hepatitis B and HIV - enters phase II
- Going live – immune cell activation in multiple sclerosis
- DNA damage: The dark side of respiration
- EMBO announces new members for 2013
- Evotec and Harvard University to collaborate on development of new class of antibacterials
- Carl Zeiss Meditec improves its results in first six months of financial year 2012/2013